Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
复制标题
DOI：
10.1371/journal.pone.0016408
复制
发表时间：
2011-02-24
期刊：
影响因子：
3.7
通讯作者：
Ohyashiki JH
中科院分区：
文献类型：
--
作者：
Ohyashiki K;Umezu T;Yoshizawa S;Ito Y;Ohyashiki M;Kawashima H;Tanaka M;Kuroda M;Ohyashiki JH
我们开展了一项研究，以评估非霍奇金淋巴瘤(NHL)患者血浆中miR-92a的临床相关性，因为miR-17-92多顺反子miRNA簇在淋巴瘤发生中发挥关键作用，并影响新血管生成。与健康人(P<；0.0001)相比，NHL患者的血浆miR-92a值极低(P<；5%)，与淋巴瘤亚型无关。极低水平的miR-92a血浆水平在完全应答期升高，但未达到正常范围，复发期血浆水平再次降低。血浆miR-92a水平低于临界值的CR或CR患者的复发率明显高于miR-92a正常者。因此，本研究结果表明，血浆miR-92a值不仅可作为诊断淋巴瘤的一种新的生物标志物，而且可用于监测淋巴瘤化疗后的病情。
We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis. Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level. The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.